← Leaderboards
Zhongxing Liao
University Of Tx Md Anderson Can Ctr
$4,193,578
Attributed
$4,193,578
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $788.7K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,193,578 · 2
By mechanism
R01$3,805,993 · 1
R21$387,585 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Albert Koong$7,304,561
- Sam Beddar$2,871,036
- Jerimy C. Polf$1,927,458
- Katherine Arnold Hutcheson$5,107,957
- Wei Liu$2,307,130
Others in their field
Other Emerging Leaders on “Prevent”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$141,293,697
- Kimberly Smith · Ppd Development Lp$115,671,664
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$112,282,390
- Beth Baseler · Leidos Biomedical Research, Inc.$100,071,064
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
Research focus
PreventPhotonsHeartMalignant NeoplasmsNon-Small-Cell Lung CarcinomaPatternCardiotoxicityEventMalignant Neoplasm Of LungLungChestBlood Specimen3-DimensionalPatient SelectionCancer PatientAccountingClinical PracticeDoseHeart DamageCardiacBiological MarkersHigh RiskAftercareProspective
Grant awards (7)
Risk prediction and longitudinal assessment of cardiotoxicity and functional capacity trajectory in NSCLC patients$739,566
R01 · FY2025 · HL · contact PI
Risk prediction and longitudinal assessment of cardiotoxicity and functional capacity trajectory in NSCLC patients$733,032
R01 · FY2024 · HL · contact PI
Risk prediction and longitudinal assessment of cardiotoxicity and functional capacity trajectory in NSCLC patients$764,190
R01 · FY2023 · HL · contact PI
Risk prediction and longitudinal assessment of cardiotoxicity and functional capacity trajectory in NSCLC patients$780,553
R01 · FY2022 · HL · contact PI
Risk prediction and longitudinal assessment of cardiotoxicity and functional capacity trajectory in NSCLC patients$788,652
R01 · FY2021 · HL · contact PI
Proton Therapy to Reduce Heart Damage for Lung Cancer Patients$176,175
R21 · FY2020 · CA · contact PI
Proton Therapy to Reduce Heart Damage for Lung Cancer Patients$211,410
R21 · FY2019 · CA · contact PI